On March 6, BRIO PHARMA, the Japanese subsidiary of Ohsong Pharm Co., Ltd. (CEO, Kim Young-Joong), a Korea-Japan based pharmaceutical trading company, officially opened its new office in Tokyo.  The photo above shows the opening ceremony of the office. The event was attended by executives and employees of Ohsong Pharm Co., Ltd. And its affiliates, as well as executives and employees of Japan’s BRIO PHARMA KOTRA, and officials from the Tokyo Metropolitan Government.

In July 2017, Brio Pharma, established with 100% investment from Ohsong Pharm Co., Ltd. relocated its office to Otemachi in central Tokyo. The company is currently in the process of completing Japan’s first domestic pharmaceutical manufacturing and sales license, which is expected to be granted in March.

Although the licensing requirements are strict, securing this pharmaceutical manufacturing and sales license will provide a solid foundation for managing various activities, including licensing applications, clinical and non-clinical trials, and pharmaceutical wholesale operations.

Brio Pharma offers a range of services such as market research, patent analysis, and product selection for pharmaceutical and biotech companies, aiming to enter the Japanese market. The company collaborates with experienced local Japanese experts and Korean staff to support these efforts. Additionally, Brio Pharma operates a liaison office in Seoul to ensure efficient communication with Korean partners.

Considering the conservative culture of the Japanese pharmaceutical industry, the experience and know-how accumulated in japan is essential. We are committed to doing our best to support Korean pharmaceutical companies in entering the challenging Japanese market.